
Validea's guru fundamental report rates Pfizer (PFE) at 85% using Meb Faber's Shareholder Yield Investor model, which prioritizes companies returning cash to shareholders via dividends, buybacks, and debt paydown. This score indicates 'some interest' for investors employing this strategy, positioning PFE as a large-cap growth stock within the Biotechnology & Drugs sector based on its underlying fundamentals and valuation.
Pfizer (PFE) has received a moderately positive rating of 85% from Validea's quantitative model based on Meb Faber's Shareholder Yield strategy, which targets companies returning cash to shareholders. This score, classifying PFE as a large-cap growth stock in the Biotechnology & Drugs sector, suggests 'some interest' from the model, as it surpasses the 80% threshold but remains below the 90% 'strong interest' level. The stock passed several key criteria, including Net Payout Yield, Quality and Debt, Valuation, and Relative Strength. However, it is critical to note that despite the model's focus, PFE specifically failed the 'Shareholder Yield' test. This apparent contradiction indicates that while the overall composite score is favorable due to strengths in other areas, the company's capital return profile has a specific weakness according to the strategy's detailed screening.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.60
Ticker Sentiment